Editas Medicine Reports New In Vivo Proof of Concept Data in an Undisclosed Liver Target at the American Society of Gene and Cell Therapy Annual Meeting
MWN-AI** Summary
Editas Medicine, Inc. (Nasdaq: EDIT), a leader in gene editing, showcased promising in vivo proof-of-concept data concerning a novel treatment targeting an undisclosed liver condition at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT). The findings were presented by Editas scientists through a poster session at the conference held in New Orleans on May 14, 2025.
Utilizing CRISPR/Cas RNA delivered through lipid nanoparticles (LNPs), the research aimed at modifying a specific liver gene. This unique approach emulated a naturally occurring protective gene variant, leading to significant upregulation of the target gene. Results demonstrated a remarkable reduction of over 80% in disease-associated biomarkers in mice, validating the efficacy of the experimental treatment.
Key findings indicated that a dose-response study in a specific mouse model resulted in approximately 70% editing of the target gene in the liver, coupled with substantial upregulation of the target protein. Additionally, CRISPR/Cas editing in cynomolgus monkey liver cells reflected similar success, with over 50% target gene editing and a striking 15-fold increase in protein levels.
Dr. Linda C. Burkly, Editas' Executive Vice President and Chief Scientific Officer, expressed optimism about the implications of these results, suggesting that the therapeutic strategy could be transformative for treating liver diseases. Editas plans to disclose more information about the disease target and development candidate later in 2025.
Further details on the undisclosed liver target will also be revealed during an oral presentation at the TIDES USA 2025 conference, signifying Editas Medicine’s ongoing commitment to advancing innovative gene editing solutions for serious conditions worldwide.
MWN-AI** Analysis
Editas Medicine (Nasdaq: EDIT) has announced promising in vivo proof-of-concept data regarding a novel liver-targeted gene therapy utilizing CRISPR/Cas technology, showcased at the American Society of Gene and Cell Therapy Annual Meeting. The results indicate a robust approach to gene editing that has achieved significant upregulation of a target protein and a meaningful reduction in disease-associated biomarkers in mouse models.
The positive data from Editas aligns with increasing investor interest in gene editing technologies, particularly those addressing liver diseases, which represent a considerable market opportunity. With liver diseases such as non-alcoholic fatty liver disease and genetic disorders gaining prevalence, a successful therapy could position Editas as a leader in this therapeutic space.
Analysts should tune into key upcoming milestones, including further details on the undisclosed liver target, expected to be unveiled in May at the TIDES USA conference. The company's ability to demonstrate efficacy and safety in non-human primates is crucial, as it sets the stage for future clinical trials.
Furthermore, the strategic use of lipid nanoparticles (LNPs) to deliver CRISPR/Cas components enhances the therapeutic potential, offering advantages in targeting and delivery that can differentiate Editas from competitors. Given the significant reductions in disease biomarkers observed, investors may view this as a validation of Editas’ innovative platform.
As the company progresses toward its clinical development phases, continued communication regarding their development pipeline and results will be pivotal for maintaining investor confidence. Current market sentiment appears optimistic, and if further data corroborates these findings, Editas could see substantial stock appreciation. However, it is essential to remain cautious and aware of typical biotech volatility, especially around upcoming presentations and announcements. Overall, Editas Medicine presents an intriguing investment opportunity in the burgeoning field of gene editing therapies.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
In vivo CRISPR Editing Results in Functional Upregulation of a Liver Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice
CAMBRIDGE, Mass., May 13, 2025 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (Nasdaq: EDIT), a pioneering gene editing company, today shared in vivo proof of concept data supporting the development of a potentially first-in-class treatment for an undisclosed liver target in a poster presentation at the 28th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) in New Orleans. Editas scientists will present the data in a poster session on Wednesday, May 14, 2025, 5:30 p.m. – 7:00 p.m. CT (6:30 p.m. – 8:00 p.m. ET).
An in vivo editing strategy using lipid nanoparticles (LNPs) with CRISPR/Cas RNA cargo was employed for an undisclosed liver target gene. The strategy mimics a naturally occurring, protective variant, resulting in upregulation of the target gene. This resulted in meaningful reduction in the clinically relevant disease-specific biomarker in mice.
Key findings include:
- An in vivo dose-response study in a disease-specific mouse model utilizing LNPs to deliver CRISPR/Cas-based cargo demonstrated maximal liver editing of the target gene (~70%) and resulted in robust target protein upregulation with >80% disease biomarker reduction.
- Editing and subsequent upregulated expression of the target gene in cynomolgus monkey hepatocytes treated with CRISPR/Cas-based editing cargo also achieved >50% target gene editing and >15-fold protein upregulation.
“This in vivo proof of concept data in an undisclosed liver disease target confirms our ability to achieve maximal target gene editing within hepatocytes and clinically meaningful reduction in disease biomarkers. We believe this therapeutic approach will be transformative in the future treatment of this disease,” said Linda C. Burkly, Ph.D., Executive Vice President and Chief Scientific Officer, Editas Medicine. “We are making significant progress towards the clinic and look forward to sharing the disease target and our development candidate later this year.”
Additional data on the undisclosed liver target will be shared in an oral presentation on May 21 at TIDES USA 2025: Oligonucleotide & Peptide Therapeutics Conference in San Diego.
Poster Presentation Details:
Title: In Vivo CRISPR Editing of Genetic Regulatory Regions Results in Functional Upregulation of Target Protein and Meaningful Reduction of Disease-Associated Biomarker in Mice
Session Date and Time: Wednesday, May 14, 2025, 5:30 p.m. – 7:00 p.m. CT
Session Title: Wednesday Poster Reception
Presentation Room: Poster Hall, Hall 12
Final Abstract Number: AMA351
Additional Editas Medicine presentations are below. Abstracts can be accessed on the ASGCT website , and the presentations will be posted on the Editas Medicine website during the conference.
Oral Presentation:
Title: In Vivo Delivery of HBG1/2 Promoter Editing Cargo to HSC of Humanized Mouse and Non-Human Primate with Lipid Nanoparticles
Session Date and Time: Wednesday, May 14, 2025, 1:30 p.m. – 1:45 p.m. CT
Session Title: Translational Applications of Base and Prime Editors
Room: 265-268
Final Abstract Number: AMA353
Poster Presentations:
Title: Design and Development of Improved LNP Targeting Ligands for In Vivo Hematopoietic Stem Cell Editing
Session Date and Time: Tuesday, May 13, 2025, 6:00 p.m. – 7:30 p.m. CT
Session Title: Tuesday Poster Reception
Presentation Room: Poster Hall, Hall 12
Final Abstract Number: AMA245
Title: Design of Chemically Modified AsCas12a Guide RNAs for Increased Potency of LNP-Delivered Gene Editing Cargos
Session Date and Time: Tuesday, May 13, 2025, 6:00 p.m. – 7:30 p.m. CT
Session Title: Tuesday Poster Reception
Presentation Room: Poster Hall, Hall 12
Final Abstract Number: AMA420
Title: In Vivo Gene Editing and Disease-Associated Biomarker Reduction for Multiple Liver Targets in Non-human Primate Using AsCas12a Nuclease Delivered by LNP
Session Date and Time: Wednesday, May 14, 2025, 5:30 p.m. – 7:00 p.m. CT
Session Title: Wednesday Poster Reception
Presentation Room: Poster Hall, Hall 12
Final Abstract Number: AMA640
About Editas Medicine
As a pioneering gene editing company, Editas Medicine is focused on translating the power and potential of the CRISPR/Cas12a and CRISPR/Cas9 genome editing systems into a robust pipeline of in vivo medicines for people living with serious diseases around the world. Editas Medicine aims to discover, develop, manufacture, and commercialize transformative, durable, precision in vivo gene editing medicines for a broad class of diseases. Editas Medicine is the exclusive licensee of Broad Institute’s Cas12a patent estate and Broad Institute and Harvard University’s Cas9 patent estates for human medicines. For the latest information and scientific presentations, please visit www.editasmedicine.com .
Media and Investor Contact:ir@editasmed.com
FAQ**
What specific liver disease is Editas Medicine Inc. EDIT targeting with its CRISPR-based treatment, and what are the potential implications of this breakthrough for patients?
How do the in vivo editing results in mice, including ~70% liver editing and >80% disease biomarker reduction, compare to other gene editing approaches utilized by Editas Medicine Inc. EDIT?
Can you provide further insights into the lipid nanoparticles (LNPs) delivery mechanism used in the study by Editas Medicine Inc. EDIT and its significance for safe and effective gene delivery?
What are the next steps planned by Editas Medicine Inc. EDIT following the presentation of these promising results, particularly regarding the timeline for potential clinical trials?
**MWN-AI FAQ is based on asking OpenAI questions about Editas Medicine Inc. (NASDAQ: EDIT).
NASDAQ: EDIT
EDIT Trading
-2.57% G/L:
$2.465 Last:
588,093 Volume:
$2.60 Open:
